이지바이오
Financials
Valuation Metrics
이지바이오's Market Cap is ₩2008B. At end of 2025 it was ₩1922B. Ranked #821 of 2,436 in KR market (top 34%), #376 of 1,649 on KOSDAQ (top 23%), #30 of 84 in Food, Beverage & Tobacco (top 36%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 200.81B KRW | KR#821/2,436 Sec#30/84 |
| Revenue | 490.70B KRW | KR#618/2,436 Sec#39/84 |
| Net Income | 35.17B KRW | KR#462/2,436 Sec#19/84 |
| Total Assets | 361.87B KRW | KR#907/2,436 Sec#46/84 |
| Net Assets | 120.30B KRW | KR#1,272/2,436 Sec#55/84 |
| Employees | 134 | KR#1,404/2,436 Sec#57/84 |
| Value | ||
| P/E | 5.71x | KR#355/2,436 Sec#22/84 |
| P/B | 1.67x | KR#1,861/2,436 Sec#79/84 |
| PEG | 0.06x | KR#283/2,436 Sec#13/84 |
| P/S | 0.41x | KR#783/2,436 Sec#59/84 |
| EV/EBITDA | 6.48x | KR#337/2,436 Sec#19/84 |
| FCF Yield | 14.33% | KR#466/2,436 Sec#36/84 |
| Profitability | ||
| ROE | 29.24% | KR#51/2,436 Sec#2/84 |
| ROA | 9.72% | KR#206/2,436 Sec#4/84 |
| Op. Margin | 10.01% | KR#491/2,436 Sec#7/84 |
| Revenue Growth | 11.77% | KR#860/2,436 Sec#15/84 |
| Earnings Growth | 102.26% | KR#417/2,436 Sec#14/84 |
| Financial Health | ||
| Debt Ratio | 200.81% | KR#1,721/2,436 Sec#47/84 |
| Total Debt | 162.30B KRW | KR#559/2,436 Sec#36/84 |
| FCF | 28.78B KRW | KR#426/2,436 Sec#31/84 |
| Cash | 44.77B KRW | KR#804/2,436 Sec#38/84 |
| Current Ratio | 1.23x | KR#1,547/2,436 Sec#36/84 |
| Net Debt/EBITDA | 2.39x | KR#919/2,436 Sec#29/84 |
| Dividend | ||
| Div. Yield | 4.14% | KR#413/2,436 Sec#21/84 |
| Div. Growth | 25.00% | KR#378/2,436 Sec#16/84 |
| Performance | ||
| 1Y Return | 11.17% | KR#517/2,436 Sec#11/84 |
| 1M Return | -3.96% | KR#1,297/2,436 Sec#70/84 |
| From 52W High | -29.09% | KR#381/2,436 Sec#32/84 |
| 1Y MDD | -28.91% | KR#182/2,436 Sec#15/84 |
| Trading | ||
| Volume | 198,317 shares | KR#579/2,436 Sec#13/84 |
| Foreign Own. | 6.14% | KR#709/2,436 Sec#22/84 |
| Per Share | ||
| EPS | 1,010 KRW | KR#617/2,436 Sec#27/84 |
| BPS | 3,461 KRW | KR#1,719/2,436 Sec#67/84 |
Company Info
Established in 2020 through a spin-off from Easy Holdings Co., Ltd., the company was re-listed on KOSDAQ in the same year. It specializes in manufacturing and selling animal pharmaceuticals, compound feed, and functional foods, alongside developing natural antimicrobial substances as antibiotic alternatives. The company differentiates its piglet feed with dedicated production facilities and processing technology, while developing high value-added feed additives based on fermentation engineering. Easy Bio was established in 2020 and is headquartered in Gangnam-gu, Seoul.